LLY

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."

Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

Retrieved on: 
Thursday, March 7, 2024
Big Night, Eli Lilly and Company, Alzheimer's disease, Obesity, FDA, Health, Lilly, Get Better, Patient, Medicine, Disease, Science, Patient safety, Research, LLY, Shame, Pharmaceutical industry

INDIANAPOLIS, March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.

Key Points: 
  • INDIANAPOLIS, March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity.
  • Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.
  • As a continuation of the larger campaign, Lilly will air two films - Shame and Big Night .
  • Shame, unveiled during Obesity Care Week, is designed to increase the dialogue about obesity as a serious disease and reinforce that there is no place for shame in the conversation around it.

Lilly to Participate in Cowen's 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 20, 2024
Eli Lilly and Company, LLY, Conference

INDIANAPOLIS, Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024.

Key Points: 
  • INDIANAPOLIS, Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024.
  • Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay of the presentation will be available on this same website for approximately 90 days.

Philip Johnson to Retire as Lilly Treasurer

Retrieved on: 
Friday, February 9, 2024
LLY, Institutional Investor, Mentorship, Eli Lilly and Company, Lilly, Patient, Pharmaceutical industry

INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.

Key Points: 
  • INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.
  • "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at Lilly.
  • Throughout his tenure, Johnson supported a variety of operations, including Lilly affiliates in Japan and Spain, global manufacturing and quality organizations, and business development activities.
  • He led Lilly's investor relations group for 11 years and was consistently named Top Investor Relations Officer by Institutional Investor.

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Retrieved on: 
Thursday, January 25, 2024
Patient, Research, Executive Committee, Woman, Eli Lilly and Company, Quality control, Retirement, LLY, Pharmaceutical industry

INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.

Key Points: 
  • INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.
  • "Johna's career has been built on her commitment to ensuring that our medicines are produced with the highest quality standards.
  • "During her tenure as leader of Global Quality, Johna has overseen significant expansion, modernization of systems and improvements in our processes and team.
  • Norton has been with Lilly since 1990, starting as an analytical chemist and moving on to hold various leadership positions in quality assurance and quality control.

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

Retrieved on: 
Tuesday, January 23, 2024
Child, Hearing loss, Lilly, Clinical trial, Gene, Medicine, Sant Joan, ABR, Eli Lilly and Company, Genetic testing, Division, HL, Hospital, ARO, FDA, Physician, Late, Hearing, Research, Diagnosis, LLY, SVP, Pharmaceutical industry

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss. Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.

Key Points: 
  • Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.
  • Both the surgical administration procedure and the investigational therapy were well tolerated, and no serious adverse events were reported.
  • Millions of individuals worldwide have disabling hearing loss because one of their genes generates an incorrect or incomplete version of a protein the ear requires for hearing.
  • OTOF-mediated hearing loss is the first monogenic form of hearing loss to be investigated as part of a gene therapy clinical trial.

Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

Retrieved on: 
Tuesday, January 23, 2024
Eli Lilly and Company, LLY, Lilly, Pharmaceutical industry

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024.

Key Points: 
  • INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024.
  • Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance.
  • Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay will also be available on the website following the conference call.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

Retrieved on: 
Thursday, January 4, 2024
Eli Lilly and Company, LLY, Obesity, Patient, Hope, Health, Diabetes, Migraine, Conditional sentence, Pharmaceutical industry

INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.

Key Points: 
  • INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.
  • LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.
  • "LillyDirect offers more choices in how and where people access healthcare, including a convenient home delivery option to fill Lilly medicines they have been prescribed."
  • For patients living with obesity, migraine and diabetes, LillyDirect offers:
    LillyDirect Pharmacy Solutions, a digital pharmacy for select Lilly medicines powered by third party online pharmacy fulfillment services.